Hepatitis B virus transcripts from conserved genomic region (HBV RNA)

Hepatitis B virus (HBV) transcripts are the essential RNA molecules produced from the viral covalently closed circular DNA (cccDNA) or integrated DNA during infection. These transcripts include the pregenomic RNA (pgRNA), which serves as the template for reverse transcription, and various messenger RNAs (mRNAs) that encode viral proteins such as the surface antigen (HBsAg), core antigen (HBcAg), and polymerase (Source: NIH, PMC5450951). Therapeutic strategies targeting conserved genomic regions of these transcripts, such as RNA interference (RNAi) and antisense oligonucleotides (ASOs), aim to degrade the RNA and suppress the production of all viral proteins (Source: PubMed, 33164343). By significantly reducing the viral antigen burden, particularly HBsAg, these therapies are designed to alleviate the suppression of the host immune system and facilitate a functional cure for chronic hepatitis B (Source: GSK, Bepirovirsen Press Release). This approach is particularly effective because targeting conserved regions ensures activity across different HBV genotypes and minimizes the risk of viral resistance (Source: Arrowhead Pharmaceuticals, JNJ-3989). Overall, these transcripts represent a critical bottleneck in the viral life cycle and a high-value target for modern antiviral drug development.

Other names

HBV mRNAHBV pregenomic RNApgRNAHBV conserved genomic region transcriptsHepatitis B virus RNA

Targeted degradation of viral RNA transcripts through RNA interference (siRNA) or RNase H-mediated cleavage (ASO), which inhibits the production of viral proteins and the replication of the viral genome.